Compsn. containing natural phenolic compound for preventing or treating elevated blood liquid level-related diseases

A composition and disease technology, applied in the direction of carbohydrate active ingredients, drug combination, cardiovascular system diseases, etc., can solve the problems of expensive drugs, adverse side effects of the central nervous system, etc.

Inactive Publication Date: 2001-10-17
KOREA RES INST OF BIOSCI & BIOTECH
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, these drugs are very expensive and their chronic administration is known to cause adverse side effects in the central nervous system
In addition, although lovastatin  and simvastatin  Plasma LDL cholesterol levels can be

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compsn. containing natural phenolic compound for preventing or treating elevated blood liquid level-related diseases
  • Compsn. containing natural phenolic compound for preventing or treating elevated blood liquid level-related diseases
  • Compsn. containing natural phenolic compound for preventing or treating elevated blood liquid level-related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Additionally, percentages of solids in solid mixtures, percentages of liquids in liquids, and percentages of solids in liquids given below are based on wt / wt, vol / vol, and wt / vol, respectively, and unless otherwise stated, all reactions were at room temperature next. Example 1: Toxicity of Oral Administration of Tannin, Gallic Acid or Ellagic Acid

[0032] Thirty-six 7-week-old specific pathogen-free ICR female mice, 18 female mice weighing approximately 25-29 g each, and 18 male mice weighing approximately 34-38 g were maintained at an ambient temperature of 22 ± 1 ℃, relative humidity 55±5% and photoperiod 12L / 12D. Feed (Cheiljedang Co., mouse and rat feed) and water were sterilized and fed to the mice.

[0033] Tannins, gallic acid or ellagic acid purchased from Aldrich-Sigma Chemical Co. (St.Louis, MO, U.S.A) were dissolved in 0.5% Tween 80 to a concentration of 500 mg / ml, and the solution was orally administered to mice, The dosage is 0.2ml / 20g mouse body weight...

Embodiment 2

[0035] food group

[0036] During 6 weeks, the rats were freely fed with the designated food and water, the intake was recorded daily, and the rats were weighed every 7 days, and then the records were analyzed. All rats showed normal growth rates and there were no significant differences among the three groups in terms of food intake and weight gain. (Step 2) Determination of total cholesterol, HDL-cholesterol and neutral lipid content in blood

[0037] The effect of administration of tannin or gallic acid on plasma cholesterol and neutral lipid levels in rats was determined as follows.

[0038] Group

[0039] It can be seen from Table 2 that the total plasma cholesterol levels were 35% and 31% lower in the tannin and gallic acid groups than in the control group, respectively. The ratio of HDL-C / total-C in the tannin and gallic acid groups was 54% and 21% higher than that in the control group, respectively. In addition, the neutral lipid content of the t...

Embodiment 3

[0040] To determine the effect of feeding tannins or gallic acid on ACAT activity in rats, microsomes were isolated from ready-to-use liver tissue as the enzyme source.

[0041] Each 1g of liver from each group of rats in Example 2 was mixed in 5ml of homogenization medium (0.1MKH 2 PO 4 , pH7.4, 0.1mM EDTA and 10mM β-mercaptoethanol) homogenized. The homogenate was centrifuged at 3000xg and 4°C for 15 minutes, and the supernatant thus obtained was centrifuged at 15000xg and 4°C for 15 minutes to obtain a supernatant. The supernatant was placed in an ultracentrifuge tube (Beckman) and centrifuged at 100000xg and 4°C for 1 hour to obtain a microsomal pellet, which was then suspended in 3 ml of homogenization medium and centrifuged at 100000xg and 4°C 1 hour. The resulting pellet was suspended in 1 ml of homogenization medium. The protein concentration in the resulting suspension was determined by the Lowry method and then adjusted to 4-8 mg / ml. The resulting suspension was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A method for treating or preventing an elevated blood lipid level-related diseases such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and hepatic diseases in a mammal, which comprises administering thereto an effective amount of tannin, gallic acid or ellagic acid.

Description

field of invention [0001] The present invention relates to a pharmaceutical composition for treating or preventing diseases associated with elevated blood lipid levels in mammals, such as hyperlipidemia, arteriosclerosis, angina pectoris, stroke and liver disease, the composition comprising an effective amount of Tannin, gallic acid or ellagic acid and a pharmaceutically acceptable carrier; the present invention also relates to a functional food or beverage composition for treating or preventing such diseases, which includes an effective amount of tannin, gallic acid or ellagic acid acid. Background of the invention [0002] It has been reported that blood lipids, especially cholesterol and triglycerides, are closely related to various diseases such as coronary heart and circulation diseases, such as arteriosclerosis and hypercholesterolemia, and fatty liver. Cholesterol, a fatty sterol, is a blood lipid produced in the liver from saturated fat. Triglycerides are another c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23C9/13A21D2/14A21D2/18A21D2/36A21D13/00A21D13/08A23C9/152A23C19/093A23F3/14A23G1/00A23G1/30A23G3/00A23G3/34A23G3/36A23G4/00A23G9/32A23G9/44A23G9/52A23L1/30A23L2/38A23L2/52A23L2/56A23L7/109A23L13/40A23L23/00A23L27/60A23L35/00A61K31/045A61K31/192A61K31/37A61K31/70A61K31/7024A61P1/16A61P3/06A61P9/10C07D493/04C07H13/08C12G3/00
CPCA23L2/56A23G3/368A21D2/14A21D2/145A21D2/181A21D2/36A23C9/152A23F3/14Y10S514/824A61K31/70A23L1/3002A23L33/105A61P1/16A61P3/06A61P9/10A61K31/35A61K31/19A61K2300/00A61K31/045
Inventor 卜成海郑泰淑裴基焕朴镛福崔明淑文锡植权容国李恩淑玄柄和崔良圭李哲浩李世峰朴永培金孝洙
Owner KOREA RES INST OF BIOSCI & BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products